Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03724175 · ClinicalTrials.gov registry record · Phase 2
The Role of Secondary Bile Acids in Intestinal Inflammation
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03724175: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT03724175 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03724175, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The cause of Inflammatory bowel disease (IBD) is unknown, but intestinal bacteria-involved in the production of molecules that impact health-are widely accepted to play a key role. A significant proportion of IBD patients with pouches (surgically created rectums after the diseased colon is removed) continue to have inflammation similar to their previous disease. Only a few microbes are known to have the capability to modify primary bile acids (PBAs) made by the liver to secondary bile acids (SBAs). SBAs are some of the most common metabolites in the colon and play key roles in several diseases. In this study the investigators will investigate if ursodeoxycholic acid (UDCA) may reduce inflammatory markers and improve quality of life (as assessed by validate survey) in those subjects with active antibiotic refractory or antibiotic dependent pouchitis.
Interventions
- DRUG ursodiol (ursodeoxycholic acid, UDCA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2026-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03724175
The ClinicalTrials.gov registry entry for NCT03724175 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ursodiol (ursodeoxycholic acid, UDCA) is the first listed.
NCT03724175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03724175 about?
NCT03724175 is a clinical study titled "The Role of Secondary Bile Acids in Intestinal Inflammation". The cause of Inflammatory bowel disease (IBD) is unknown, but intestinal bacteria-involved in the production of molecules that impact health-are widely accepted to play a key role. A significant proportion of IBD patients with pouches (surgically created rectums after the diseased colon is removed) ...
What is the current status of trial NCT03724175?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2019-08-26. Estimated completion is 2026-03-02.
What interventions are being tested in trial NCT03724175?
The interventions under investigation include: ursodiol (ursodeoxycholic acid, UDCA) (DRUG).
Who is sponsoring clinical trial NCT03724175?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.